A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed comprising: (a) using a first device to generate smoke, aerosol or vapour from a target in vitro or ex vivo cell population; (b) mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and (c) analysing said spectrometric data in order to identify and/or characterise said target cell population or one or more cells and/or compounds present in said target cell population.

A method of predicting a sepsis condition in a subject, comprising: a. determining a level of a biomarker in a sample of said subject, wherein the biomarker is of structure (I): Formula (I) or a salt thereof; and b. comparing said level to a predetermined reference value of the biomarker, wherein an elevated biomarker level is indicative of the risk of the sepsis condition.

##STR00001##

The invention relates to in vitro methods for detecting bacteremia, for selecting a therapy for a subject with cystic fibrosis or for a subject with systemic inflammatory response syndrome and for selecting a subject with cystic fibrosis or with systemic inflammatory syndrome for a particular therapy based on the expression levels of a gene selected from tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF in a blood sample from the subject. The invention also relates to a kit comprising a TLR-4 agonist and a reagent specific for determining the level of at least one cytokine selected from the group consisting of tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF and to the uses of this kit.

The present invention relates to vitro method for analysing a liquid sample as to the presence, identity and properties of microbes comprising: a) isolating microbes from the liquid sample; b) analysing said microbes spectroscopically by means of spontaneous Raman spectroscopy; and c) determining antibiotic susceptibility of said microbes spectroscopically by means of spontaneous Raman spectroscopy. The present invention also refers to device for analysing a liquid sample as to the presence, identity and properties of microbes, wherein the device comprises as a first unit (i) a chip comprising a filtering unit and an antibiotics exposure unit capable of determining the susceptibility of microbes to an antibiotic; as a second unit (ii) a Raman spectroscopy system; and as a third unit (iii) an evaluation module which is coupled to the Raman spectroscopy system.

Methods for determining bacterial identity and susceptibility or resistance to antibiotic or antimicrobial agents are provided. In one embodiment, the bacteria is cultured in the presence or absence or the antibiotic agent to generate a plurality of primary cultures, which are then cultured in the presence or absence of transforming phages to generate a first secondary culture that comprise transformed bacteria that have been treated with the antibiotic agent and a second secondary culture that comprises transformed bacteria that have not been treated with the antibiotic agent. The recombinant phages are specific to the bacteria and comprise a heterologous marker. The susceptibility or resistance of the bacteria to the antibiotic or antimicrobial agent is determined by comparing a level or activity of the marker in the first and second secondary cultures.

The invention relates to protein biomarkers representing protein biomarker signatures to assess a patient who may develop sepsis, or who may have developed sepsis. The invention relates in particular to methods for assessment or monitoring with respect to diagnosis, prediction or progression of sepsis in a patient, as well as the responsiveness to, or selection of suitable agents for, the treatment of sepsis. The invention also relates to the use of protein biomarkers representing protein biomarker signatures for sepsis, and associated kits and system.

The invention relates to a method for detecting a dengue infection in a patient blood sample, comprising the steps: a) Performing an analysis of prespecified parameters of blood platelets and prespecified types of blood cells in the sample and determining parameter values for the prespecified parameters of the platelets and the prespecified types of cells; b) Obtaining sample parameters from the values determined in step a); and c) Evaluating the sample parameters in relation to a prespecified criterion, wherein, if the criterion is fulfilled, a dengue infection is present.

The present invention provides self-contained systems for performing an assay for determining a chemical state, the system including a stationary cartridge for performing the assay therein, at least one reagent adapted to react with a sample; and at least one reporter functionality adapted to report a reaction of the at least one reagent with said sample to report a result of the assay, wherein the at least one reagent, the sample and the at least one reporter functionality are contained within the cartridge.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.

The invention provides assays and methods for diagnosing and treating infectious diseases. The invention relates in some embodiments to urinary biomarkers and their use in the differential diagnosis of bacterial and viral infections. The invention further relates to means for determining and providing correct treatment to infection in a non-invasive manner, while minimizing antibiotic misuse.